Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04504669
Title First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors AstraZeneca

Advanced Solid Tumor

cervical cancer

lung small cell carcinoma

head and neck squamous cell carcinoma

clear cell renal cell carcinoma

triple-receptor negative breast cancer


lung non-small cell carcinoma

stomach cancer


AZD8701 + Durvalumab


Age Groups: adult | senior
Covered Countries USA | FRA | ESP | CAN

No variant requirements are available.